Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Up 24.3% in February

Oragenics, Inc. (NYSEAMERICAN:OGEN) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 570,220 shares, an increase of 24.3% from the February 12th total of 458,764 shares. Approximately 14.9% of the shares of the company are short sold. Based on an average daily trading volume, of 844,062 shares, the days-to-cover ratio is currently 0.7 days. Based on an average daily trading volume, of 844,062 shares, the days-to-cover ratio is currently 0.7 days. Approximately 14.9% of the shares of the company are short sold.

Oragenics Stock Down 4.0%

NYSEAMERICAN OGEN traded down $0.03 during trading hours on Tuesday, reaching $0.77. 130,825 shares of the company were exchanged, compared to its average volume of 617,925. The stock has a market capitalization of $3.28 million, a P/E ratio of -0.06 and a beta of 1.09. Oragenics has a 1 year low of $0.61 and a 1 year high of $9.60. The business’s 50 day simple moving average is $0.82 and its 200-day simple moving average is $1.00.

Institutional Trading of Oragenics

Hedge funds have recently made changes to their positions in the company. Clear Street LLC bought a new position in shares of Oragenics during the 2nd quarter worth $270,000. Sabby Management LLC bought a new stake in Oragenics in the 3rd quarter valued at about $77,000. DRW Securities LLC raised its stake in Oragenics by 82.4% in the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares during the period. XTX Topco Ltd purchased a new stake in Oragenics during the fourth quarter valued at about $26,000. Finally, Bank of America Corp DE lifted its holdings in Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the last quarter. 18.71% of the stock is currently owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.